SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ore Pharmaceuticals Inc.
ORXE 0.193+1.8%Aug 18 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (14)6/12/2008 3:12:18 PM
From: Mike McFarlandRead Replies (1) of 50
 
On June 10, 2008, Ore Pharmaceuticals Inc. (the "Company") received notification from the NASDAQ Stock Market ("NASDAQ") that the Company had regained compliance with Marketplace Rule 4450(a)(5) and that NASDAQ now considers the matter closed.

Previously, as disclosed in a Current Report on Form 8-K dated December 20, 2007, NASDAQ notified Ore Pharmaceuticals Inc. that the bid price of the Company's publicly held shares had closed below the minimum $1.00 per share requirement for continued listing on the NASDAQ Global Market and the Company would have six months to regain compliance or be delisted. The increase in closing bid price necessary to regain compliance was achieved through a one-for-five reverse stock split of the Company's common stock that became effective in late May 2008.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News